Edit |   |
---|---|
Antigenic Specificity | IL12B (Briakinumab biosimilar) |
Clone | monoclonal |
Host Species | Recombinant Human |
Reactive Species | human |
Isotype | IgG1 lambda |
Format | Protein A/G purified |
Size | 100 µg, 1 mg, |
Concentration | typically between 0.5-2.0 mg/ml. |
Applications | ELISA, WB |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | Briakinumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting IL12B, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Briakinumab is a human anti-IL-12 monoclonal antibody being developed for the treatment of a number of T-cell driven autoimmune diseases. It targets and neutralize interleukin-12 and interleukin-23, two proteins associated with inflammation, such as pro-inflammatory interleukins or tumor necrosis factor- alpha. Briakinumab represents a novel approach to treating psoriasis, Multiple Sclerosis, Crohn's Disease and other autoimmune and inflammatory disorders. As of 2011 drug development for psoriasis has been discontinued in the U. S. and Europe. Briakinumab targets and neutralizes interleukin-12 and interleukin-23. |
Immunogen | n/a |
Other Names | Briakinumab, IL12B, 339308-60-0 |
Gene, Accession # | CAS: 339308-60-0 |
Catalog # | abx831075 |
Price | please inquire |
Order / More Info | IL12B (Briakinumab biosimilar) Antibody from ABBEXA LTD |
Product Specific References | n/a |
U.S. Office
118 Eldridge Rd, Suite C,
Sugar Land, TX 77478 USA
Telephone: +1 832 327 7413
Netherlands Office
Abbexa BV
Wattstraat 54 2723 RD,
Zoetermeer,Netherlands
Telephone: +44 (0) 1223 755950